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abstract
PURPOSE The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed
superior outcomes for premenopausal women with hormone receptor (HR)–positive breast cancer treated with
adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone.
We previously reported the magnitude of absolute improvements in freedom from any recurrence across
a continuous, composite measure of recurrence risk to tailor decision making. With longer follow-up, we now
focus on distant recurrence.
METHODS The TEXT/SOFT HR-positive/human epidermal growth factor receptor 2 (HER2)–negative analysis
population included 4,891 women stratified by predetermined chemotherapy use. Kaplan-Meier estimates of
8-year freedom from distant recurrence were analyzed using subpopulation treatment effect pattern plot
(STEPP) methodology across subpopulations defined by the continuous composite measure of recurrence risk.
For each patient, the composite risk value was obtained from a Cox model that incorporated age; nodal status;
tumor size; grade; and estrogen receptor, progesterone receptor, and Ki-67 labeling index expression levels.
RESULTS The overall rate of 8-year freedom from distant recurrence was 91.1% and ranged from approximately
100% to 63% across lowest to highest composite risks. TEXT patients who received chemotherapy had an
average absolute improvement with exemestane plus OFS versus tamoxifen plus OFS of 5.1%, and STEPP
analysis showed improvements from less than 1% to more than 15% from lowest to highest composite risks.
SOFT patients who remained premenopausal after chemotherapy had an average 5.2% absolute improvement
with exemestane plus OFS versus tamoxifen and reached 10% across composite risks; for tamoxifen plus OFS
versus tamoxifen, the maximum improvement was approximately 3.5%. Women who did not receive che-
motherapy had a more than 97% rate of 8-year freedom from distant recurrence, and improvements with
exemestane plus OFS ranged from 1% to 4%.
CONCLUSION Premenopausal women with HR-positive/HER2-negative breast cancer and high recurrence risk, as
defined by clinicopathologic characteristics, may experience a 10% to 15% absolute improvement in 8-year
freedom from distant recurrence with exemestane plus OFS versus tamoxifen plus OFS or tamoxifen alone. The
potential benefit of escalating endocrine therapy versus tamoxifen alone is minimal for those at low recurrence risk.
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INTRODUCTION
Adjuvant endocrine therapy recommendations for
premenopausal women with hormone receptor (HR)–
positive breast cancer have changed on the basis of the
5-year results of the Tamoxifen and Exemestane Trial
(TEXT) and the Suppression of Ovarian Function Trial
(SOFT; ClinicalTrials.gov identifiers: NCT00066703 and
NCT00066690, respectively).1,2 Tamoxifen alone re-
mains the standard of care in women at low risk of
relapse, as defined by clinical and pathologic features,
and by genomic parameters, when available. Ovarian
function suppression (OFS) should be proposed to
patients at higher risk for recurrence in addition to oral
endocrine therapy with either tamoxifen or an aromatase
inhibitor.3-6
A secondary analysis of the women enrolled in TEXT
and SOFT with HR-positive/human epidermal growth
factor receptor 2 (HER2)–negative cancers estimated
ASSOCIATED
CONTENT
See accompanying
Oncology Grand
Rounds on page 1258
Appendix
Author affiliations
and support
information (if
applicable) appear
at the end of this
article.
Accepted on August
29, 2019 and
published at
ascopubs.org/journal/
jco on October 16,
2019: DOI https://doi.
org/10.1200/JCO.18.
01967
Volume 38, Issue 12 1293
Downloaded from ascopubs.org by Instituto Europeo Di Oncologia on April 16, 2020 from 193.204.098.002
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
absolute improvements in 5-year freedom from breast
cancer (including invasive locoregional, distant, or con-
tralateral breast cancer) according to recurrence risk de-
fined from clinicopathologic characteristics. The women at
high recurrence risk experienced absolute improvements
of 10% to 15%with exemestane plus OFS versus tamoxifen
plus OFS and versus tamoxifen alone, and improvements
were of at least 5% for women at intermediate risk.7 In
contrast, improvement wasminimal for women at lowest risk.
Such estimates of the absolute magnitude of improvement
can help clinicians to weigh benefits against adverse effects
in treatment decisions with individual patients.
Recent updates of TEXT and SOFT after a median follow-up
of 9 and 8 years, respectively, demonstrated significant
improvement in disease-free and overall survival with the
addition of OFS to tamoxifen in the SOFT population.8 The
combined analysis of TEXT and SOFT demonstrated sus-
tained improvements with exemestane plus OFS versus
tamoxifen plus OFS in disease-free survival, freedom from
breast cancer, and freedom from distant recurrence but not
from overall survival.8 Among the patients with HR-positive/
HER2-negative tumors, the rate of freedom from distant
recurrence was improved by 3.6% with the use of
exemestane plus OFS versus tamoxifen and by 3.5% with
exemestane plus OFS versus tamoxifen plus OFS.
Distant recurrence in a premenopausal woman has per-
sonal, economic, and social costs of greater impact than
locoregional recurrence.9 Greater toxicity may be accept-
able in prevention of distant recurrence, which generally
portends premature death as a result of breast cancer. With
extended follow-up, we are now able to refine the esti-
mates of absolute treatment effects in preventing distant
recurrence across the spectrum of recurrence risk in
the subgroup of women with HR-positive/HER2-negative
cancers.
METHODS
Study Designs
The designs and conduct of the trials have been described
previously.1,2 In both trials, eligible premenopausal women
had invasive early breast cancer assessed as 10% or
greater estrogen receptor (ER)– and/or progesterone re-
ceptor (PgR)–expressing cells by local determination. The
ethics committee at each participating center approved the
study protocols, and all patients provided written informed
consent for trial participation and mandatory tissue col-
lection for central pathology assessment. Central review of
histopathologic features and expression of ER, PgR, HER2,
and Ki-67 labeling index (Ki-67) was conducted for 84% of
trial patients in the International Breast Cancer Study Group
Central Pathology Office.10
In TEXT, all women received OFS by gonadotropin-
releasing hormone agonist triptorelin from the start of ad-
juvant therapy; after at least 6 months of triptorelin, patients
could opt for bilateral oophorectomy or ovarian irradiation.
Chemotherapy was optional and if administered, was
started concurrently with triptorelin. Between November
2003 andMarch 2011, 2,672 premenopausal women were
randomly assigned to 5 years of exemestane plus OFS
or tamoxifen plus OFS. Randomization was stratified ac-
cording to intended use of adjuvant chemotherapy and
lymph node status.
SOFTwas designed to determine the value of adding OFS to
tamoxifen and the role of exemestane plus OFS in two
cohorts of premenopausal women: those who remained
premenopausal after completion of (neo)adjuvant che-
motherapy and those for whom adjuvant tamoxifen without
chemotherapy was considered suitable treatment. Be-
tween December 2003 and January 2011, 3,066 women
were randomly assigned to 5 years of exemestane plus OFS
or tamoxifen plus OFS or tamoxifen alone. Randomization
was stratified according to prior use of chemotherapy,
lymph node status, and intended initial method of OFS (if
randomly assigned to OFS).
End Point and Statistical Considerations
The analysis population was previously defined and in-
cluded 4,891 patients with tumors centrally assessed as
HR positive/HER2 negative7 (Appendix Fig A1, online only).
Distant recurrence–free interval (DRFI) was defined as the
duration of time from random assignment until first ap-
pearance of invasive breast cancer recurrence at a distant
site; in the absence of a distant recurrence, DRFI was
censored at date of last follow-up. The median follow-up
was 9 years in TEXT and 8 years in SOFT.8
While following the approach previously described,7 the
composite measure of recurrence risk (hereafter referred to
as composite risk) was determined for the entire HR-
positive/HER2-negative analysis population by fitting a Cox
proportional hazards regression model for DRFI, stratified
by cohort (defined by trial and chemotherapy use) and
treatment assignment. This use of a stratified model pro-
vided the same risk scale for the two trials, which do not
share a common control group. Prognostic factors included
in the model and their groupings were specified a priori,
and there was no intention to optimize the model on the
basis of model selection procedures (Table 1; Appendix
Table A1, online only). For tumor grade and ER and PgR
expression, the centrally determined values were used
when available, and locally determined values were used
otherwise; Ki-67 expression was available only from central
assessment. Unknown categories were used to avoid
systematic exclusion of patients without centrally assessed
tumor features. After estimating the model parameters, the
composite risk value was calculated for each trial patient by
summing the model parameter estimates corresponding to
her observed values of clinicopathologic factors.
Nonparametric sliding window subpopulation treatment
effect pattern plot (STEPP) methodology11,12 was used to
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investigate patterns in absolute treatment effects as mea-
sured by Kaplan-Meier estimates of 8-year freedom
from distant recurrence (y-axis) across the continuum of
composite risk values (x-axis). The STEPP of the overall
analysis population had a window size of 500 and was slid
by 300 patient values to form each subpopulation. For
TABLE 1. Clinicopathologic Characteristics of the HR-Positive/HER2-Negative Analysis Population of TEXT and SOFT
Patients, %
Model
Characteristic
TEXT
Chemotherapy
(n = 1,276)
SOFT Prior
Chemotherapy
(n = 1,271)
TEXT No
Chemotherapy
(n = 991)
SOFT No
Chemotherapy
(n = 1,353)
All
Patients
(N = 4,891)
Parameter
Estimate SE
Hazard Ratio
(95% CI)
Age at random
assignment,
years
, 35 11.1 18.3 3.7 1.5 8.8 0.77 0.17 2.2 (1.6 to 3.0)
35-39 17.3 29.5 11.4 7.6 16.6 0.62 0.15 1.9 (1.4 to 2.5)
40-44 34.6 32.0 34.4 27.3 31.9 0.17 0.15 1.2 (0.9 to 1.6)
45-49 31.6 16.8 38.8 46.2 33.2 0 (ref)
$ 50 5.4 3.5 11.6 17.4 9.5 0.06 0.26 1.1 (0.6 to 1.8)
No. of positive
nodes
0 31.4 41.5 78.3 91.3 60.1 0 (ref)
1-3 44.0 40.1 21.5 8.6 28.6 0.54 0.13 1.7 (1.3 to 2.2)
$ 4 24.6 18.4 0.2 0.1 11.3 1.38 0.14 4.0 (3.0 to 5.2)
Tumor size, cm
Unknown 1.6 3.9 0.3 0.7 1.7 0.89 0.26 2.4 (1.5 to 4.0)
# 2 46.5 49.6 79.8 85.9 64.9 0 (ref)
. 2 51.9 46.5 19.9 13.5 33.4 0.58 0.11 1.8 (1.4 to 2.2)
ER expression, %
Unknown 1.8 1.3 1.7 1.0 1.5 20.20 0.62 0.8 (0.2 to 2.8)
, 50 5.1 5.9 2.0 2.7 4.0 0.14 0.18 1.2 (0.8 to 1.7)
$ 50 93.1 92.8 96.3 96.3 94.5 0 (ref)
PgR expression, %
Unknown 2.0 1.8 1.9 1.6 1.8 1.17 0.53 3.2 (1.1 to 9.1)
, 20 12.8 18.3 5.9 4.1 10.4 0.44 0.13 1.6 (1.2 to 2.0)
20-49 10.4 10.3 7.1 4.9 8.2 0.29 0.15 1.3 (1.0 to 1.8)
$ 50 74.8 69.6 85.2 89.4 79.6 0 (ref)
Tumor grade
1 12.9 15.7 25.4 37.3 22.9 0 (ref)
2 56.8 57.4 59.2 53.5 56.5 0.81 0.23 2.3 (1.4 to 3.5)
3 30.3 27.0 15.3 9.2 20.6 0.78 0.26 2.2 (1.3 to 3.6)
Ki-67 expression, %
Unknown 18.8 20.9 19.1 20.0 19.7 20.08 0.20 0.9 (0.6 to 1.4)
, 14 15.6 19.5 27.1 37.4 25.0 0 (ref)
14-19 23.0 23.8 26.4 23.9 24.2 20.10 0.20 0.9 (0.6 to 1.3)
20-25 18.3 17.0 13.6 11.2 15.1 0.26 0.20 1.3 (0.9 to 1.9)
$ 26 24.3 18.7 13.7 7.5 16.0 0.49 0.21 1.6 (1.1 to 2.5)
NOTE. Characteristics are overall and according to cohort defined by trial and chemotherapy use, and parameter estimates of the Cox proportional hazards
regression model define the composite measure of recurrence risk (n = 4,891). Values of grade and ER and PgR expression were centrally determined if
available and locally determined otherwise; Ki-67 expression was available only by central determination.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; Ki-67, labeling index Ki-67; PgR,
progesterone receptor; ref, referent group; SOFT, Suppression of Ovarian Function Trial; TEXT, Tamoxifen and Exemestane Trial.
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SOFT and TEXT, the size of windows were 420 and 300,
respectively, and slid by 120 and 150 patient values, re-
spectively. With this approach, most composite risk values
are represented in more than one subpopulation.
RESULTS
Among the 4,891 patients in the HR-positive/HER2-
negative analysis population, the clinicopathologic char-
acteristics across the four trial cohorts reflected the selection
of adjuvant chemotherapy use and whether OFS would be
received by all patients (TEXT) or by random assignment
(SOFT; Table 1; Appendix Table A1). Poor prognostic
features were more frequent on average among the co-
horts who received chemotherapy. The distribution of age
(youngest among patients in SOFT who received che-
motherapy before enrollment) reflected the SOFT eligi-
bility criteria that patients remain premenopausal after
chemotherapy.
The relationship of each of the seven clinicopathologic
characteristics individually with DRFI is shown in Figure 1.
The estimated 8-year freedom from distant recurrence
rates are shown for each characteristic by treatment group,
along with the relative treatment effects, in Figure 2 and
Appendix Figures A2 and A3 (online only) and listed in
Appendix Tables A2-A6 (online only).
The clinicopathologic characteristic with the greatest
contribution to the multivariable model for the composite
measure of recurrence risk, relative to the complementary
reference category, was four or more positive nodes fol-
lowed by tumor grade 2 or 3 and younger age (Table 1); one
to three positive nodes, tumor size greater than 2 cm, PgR
less than 20%, and Ki-67 of 26% or more contributed
similarly. ER less than 50% had a very small contribution
possibly because only 4% of patients had low ER ex-
pression described.10 The distribution of resulting com-
posite risks is illustrated for the overall population in
Figure 3 and summarized by each characteristic subgroup
in Appendix Table A7 (online only).
Overall, for the 4,891 patients, 433 distant recurrences
were reported, and the 8-year freedom from distant re-
currence rate was 91.1% (95% CI, 90.2% to 92.0%).
When the clinicopathologic features were integrated as
a composite measure of recurrence risk (median, 1.42;
interquartile range [IQR], 0.81-2.15), the 8-year freedom
from distant recurrence rate varied markedly across patient
populations, ranging from approximately 100% to 63%
among patients in the subpopulations with lowest com-
posite risks to highest composite risks, respectively (Fig 3).
As expected, the majority of distant recurrences occurred
among patients who received chemotherapy (Fig 4).
Patients for Whom Chemotherapy Was Part of
Adjuvant Therapy
The patients who received chemotherapy, whether in TEXT
or SOFT, had similar distributions of composite risk values
(Figs 5A and 5B), with a median composite risk of 2.02
(IQR, 1.43-2.71) and 2.00 (IQR, 1.42-2.68), respectively.
TEXT patients who received chemotherapy after enrollment
had an average 8-year freedom from distant recurrence
rate of 87.5% (159 distant recurrences among 1,276
patients after a median follow-up of 9 years). The average
absolute improvement in freedom from distant recurrence
with exemestane plus OFS versus tamoxifen plus OFS was
5.1% (90.0% v 84.9%; Fig 4A). The STEPP analysis
showed a distinct pattern of increasing magnitude of im-
provement with exemestane plus OFS as composite risk
increased and reached more than 15% in the sub-
population with the highest composite risks (Fig 5A).
Patients enrolled in SOFT who remained premenopausal
after chemotherapy had an 8-year freedom from distant
recurrence rate of 82.5% (216 distant recurrences among
1,271 patients after a median follow-up of 8 years). The
average absolute improvement with exemestane plus OFS
versus tamoxifen was 5.2% (86.2% v 81.0%; Fig 4B). The
STEPP analysis suggested that all patients across com-
posite risks benefited from exemestane plus OFS versus
tamoxifen, with the maximum absolute improvement of
approximately 10% (Fig 5B). The absolute improvement
with tamoxifen plus OFS versus tamoxifen alone ranged from
0 to at most approximately 3.5% for the subpopulations with
the highest composite risks.
Patients for Whom Endocrine Therapy Alone Was Planned
as Adjuvant Therapy
In contrast to the patients who received chemotherapy,
those who received only adjuvant endocrine therapy had
lower composite risks. In TEXT, the median composite risk
was 1.13 (IQR, 0.72-1.56), and in SOFT, the median was
0.81 (IQR, 0.17-1.27; Fig 5).
Among the 991 patients in TEXT who did not receive
chemotherapy, 35 experienced a distant recurrence after
a median follow-up of 9 years, and the overall 8-year
freedom from distant recurrence rate was 97.0%. The
overall absolute improvement in 8-year freedom from
distant recurrence with exemestane plus OFS versus ta-
moxifen plus OFS was less than 1% (97.4% v 96.5%;
Fig 4C). The STEPP analysis showed absolute improvement
with exemestane plus OFS only in the subpopulations with
the highest composite risks, for a maximum magnitude of
improvement in the range of 2.5% to 4% (Fig 5C).
The 1,353 patients in SOFT who did not receive chemo-
therapy had the lowest composite risks, 23 patients ex-
perienced a distant recurrence after a median follow-up of
8 years. The overall 8-year freedom from distant recurrence
rate was 98.5%, and for exemestane plus OFS, tamoxifen
plus OFS, and tamoxifen, the rate was 99.3%, 98.3%,
and 98.0%, respectively (Fig 4D). The absolute im-
provement in 8-year freedom from distant recurrence with
exemestane plus OFS versus tamoxifen ranged from
approximately 1% to 2.5%, and the improvement with
1296 © 2019 by American Society of Clinical Oncology Volume 38, Issue 12
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FIG 1. Kaplan-Meier estimates of distant recurrence (DR)–free interval in the overall hormone receptor–positive/human epidermal
growth factor receptor 2–negative analysis population according to seven clinicopathologic characteristics. (A) Age at random
assignment, (B) number of positive lymph nodes, (C) tumor size, (D) estrogen receptor (ER) expression, (E) progesterone receptor
(PgR) expression, (F) tumor grade, and (G) labeling index Ki-67 (Ki67) expression. Unknown values are omitted.
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tamoxifen plus OFS versus tamoxifen was at most 1%
(Fig 5D).
DISCUSSION
After 5 years of adjuvant endocrine therapy, breast cancer
recurrences steadily occur up to 20 years. In an Early
Breast Cancer Trialists’ Collaborative Group meta-analysis
(62,923 patients disease free after 5 years of endocrine
therapy), the risk of distant recurrence was strongly cor-
related with stage (13% and 41% in T1N0 and T2N2
disease, respectively) and tumor grade (10% and 17% for
low-grade T1N0 and high-grade disease, respectively).13 In
the absence of predictive biomarkers, standard clinico-
pathologic characteristics continue to provide meaningful
prognostic information about risk of distant recurrence and
guide treatment decision making. We put these features
together into a composite measure of recurrence risk,
which allows clinicians to better understand and estimate
the magnitude of benefit of escalating adjuvant endocrine
therapy in premenopausal women with HR-positive/HER2-
negative breast cancer.
The combined analysis of TEXT/SOFT, without regard to
tumor HER2 status, showed an average 2.1% absolute
improvement in freedom from distant recurrence at 8 years
in premenopausal women treated with an aromatase in-
hibitor versus tamoxifen with OFS.8 This benefit is com-
parable to that observed for postmenopausal women in the
Early Breast Cancer Trialists’ Collaborative Group meta-
analysis, wherein 5 years of aromatase inhibitors were
associated with a 2% absolute 10-year reduction in distant
recurrence compared with 5 years of tamoxifen (16.3% v
14.3%, respectively).14
We focused on the predominant subgroup with HR-
positive/HER2-negative cancers. As previously highlighted,15
SOFT/TEXT data suggest differential relative treatment ef-
ficacy by HER2 status and show lesser benefit of aromatase
inhibitors and greater benefit from adding OFS to tamoxifen
for HER2-positive than for HER2-negative cancers. Sec-
ondary analyses from the Hormonal Adjuvant Treatment
Bone Effects (HOBOE)16 and Adjuvant Lapatinib and/or
Trastuzumab Treatment Optimization (ALTTO)17 trials were
consistent with this observation. A closer analysis of the
HER2-positive subgroup is planned.
Among women with HR-positive/HER2-negative tumors
who received chemotherapy (on average, a higher-risk
group), an average 5% absolute improvement was
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FIG 2. Kaplan-Meier estimates of 8-year freedom from distant recurrence in seven clinicopathologic subgroups in the four patient cohorts defined
by trial and chemotherapy use according to treatment assignment. The values are listed in Appendix Tables A3 and A6. Unknown values are
omitted. ER, estrogen receptor; EXEM, exemestane; Ki-67, Ki-67 labeling index; OFS, ovarian function suppression; PgR, progesterone receptor;
SOFT, Suppression of Ovarian Function Trial; TAM, tamoxifen; TEXT, Tamoxifen and Exemestane Trial.
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achieved by escalating endocrine therapy to exemestane
plus OFS in both TEXT and SOFT. In the STEPP analysis,
the composite risk for a high-risk scenario (eg, 35 to
39 years of age, grade 3, pT2pN1a, ER and PgR of 50% or
greater, Ki-67 26% or greater; composite risk, 3.00; Ap-
pendix Fig A4A, online only) was represented in sub-
populations that had an absolute improvement greater
than the average (range, 7% to 10%). The magnitude of
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FIG 4. Kaplan-Meier estimates of distant recurrence (DR)–free interval in the four patient cohorts defined by trial and
chemotherapy use according to treatment assignment. (A) Tamoxifen and Exemestane Trial (TEXT) chemotherapy, (B)
Suppression of Ovarian Function Trial (SOFT) prior chemotherapy, (C) TEXT no chemotherapy, and (D) SOFT no chemo-
therapy. EXEM, exemestane; OFS, ovarian function suppression; TAM, tamoxifen.
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improvement with exemestane plus OFS versus tamoxifen
with or without OFS was larger in TEXT than in SOFT high-
risk patients, but improvement was consistently observed in
both cohorts. In contrast, in low-risk patients (Appendix Fig
A4C) who did not receive chemotherapy, the 8-year free-
dom from distant recurrence was improved on average by
approximately 1% in patients who received exemestane
plus OFS compared with tamoxifen alone or tamoxifen plus
Composite Risk in 
HR Positive/HER2 Negative 
Pa
tie
nt
s 
(N
o.
)
0
200
150
100
50
0 531 2
D
EXEM + OFS
TAM + OFS
TAM
Composite Risk in HR-Positive/HER2-Negative 
Subpopulations (median) 
0.06 0.54 0.89 1.30
0
20
40
60
80
100
8-
Ye
ar
 F
re
ed
om
 F
ro
m
Di
st
an
t R
ec
ur
re
nc
e 
(%
)
SOFT No Chemotherapy
Pa
tie
nt
s 
(N
o.
)
0
100
50
0 5431 2
Composite Risk in 
HR Positive/HER2 Negative
C
EXEM + OFS
TAM + OFS
0
20
40
60
80
100
8-
Ye
ar
 F
re
ed
om
 F
ro
m
Di
st
an
t R
ec
ur
re
nc
e 
(%
)
TEXT No Chemotherapy
0.46 1.07 1.611.91
Composite Risk in HR-Positive/HER2-Negative 
Subpopulations (median) 
Pa
tie
nt
s 
(N
o.
)
0
100
50
0 5431 2
Composite Risk in 
HR Positive/HER2 Negative
B
EXEM + OFS
TAM + OFS
TAM
0
20
40
60
80
100
8-
Ye
ar
 F
re
ed
om
 F
ro
m
Di
st
an
t R
ec
ur
re
nc
e 
(%
)
SOFT Prior Chemotherapy
1.22 1.73 2.13 2.77 3.04
Median Composite Risk in
HR-Positive/HER2-Negative Subpopulations 
0 5431 2
Pa
tie
nt
s 
(N
o.
)
0
100
50
Composite Risk in 
HR Positive/HER2 Negative 
A
0.89 1.421.79 2.27 3.02 3.40
0
20
40
60
80
100
8-
Ye
ar
 F
re
ed
om
 F
ro
m
Di
st
an
t R
ec
ur
re
nc
e 
(%
)
TEXT Chemotherapy
EXEM + OFS
TAM + OFS
Composite Risk in HR-Positive/HER2-Negative 
Subpopulations (median) 
FIG 5. Subpopulation
treatment effect pattern
plots of 8-year freedom
from distant recurrence
according to median
composite risk in sub-
populations and histo-
grams of the composite
risk distributions for
each of the four cohorts
in the hormone receptor
(HR)–positive/human epi-
dermal growth factor re-
ceptor 2 (HER2)–negative
analysis population accord-
ing to treatment assign-
ment. (A) Tamoxifen and
Exemestane Trial (TEXT)
chemotherapy, (B) Sup-
pression of Ovarian Func-
tion Trial (SOFT) prior
chemotherapy, (C) TEXT
no chemotherapy, and
(D) SOFT no chemo-
therapy. The horizontal
lines above each histo-
gram indicate the ranges
of composite risks in
subpopulations that are
plotted at the sub-
population median com-
posite risk value. The
vertical dashed lines in-
dicate the median com-
posite risk of 1.42 in
the overall HR-positive/
HER2-negative analy-
sis population. EXEM,
exemestane; OFS, ovar-
ian function suppression;
TAM, tamoxifen.
1300 © 2019 by American Society of Clinical Oncology Volume 38, Issue 12
Pagani et al
Downloaded from ascopubs.org by Instituto Europeo Di Oncologia on April 16, 2020 from 193.204.098.002
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
OFS in both SOFT and TEXT. The STEPP analysis sug-
gested that this low-risk scenario (eg, 40 to 44 years of age,
grade 2, pT1pN0, ER and PgR of 50% or greater, Ki-67 of
14% to 19%; composite risk, 0.89) was well characterized
by the average improvement of approximately 1%. Most
intermediate-risk patients in SOFT and TEXT received
chemotherapy. In this patient scenario (eg, 40 to 44 years
of age, grade 2, pT1pN1a, ER and PgR of 50% or greater,
Ki-67 of 20% to 25%; composite risk, 1.78; Appendix Fig
A4B), the absolute improvement with exemestane plus OFS
was estimated to be less than the average improvement of
5%. Of note, intermediate-risk patients in TEXT who did not
receive chemotherapy were estimated to have an im-
provement with exemestane plus OFS that exceeded 4%;
these patients also achieved approximately 10% improve-
ment in freedom from any breast cancer recurrence at
5 years with exemestane plus OFS.7
TEXT and SOFT results may encourage physicians to re-
consider the indication for adjuvant chemotherapy in
intermediate-risk premenopausal women with HR-positive/
HER2-negative breast cancer. The patient selection for
chemotherapy differed in SOFT and TEXT. The knowledge
that all patients would receive OFS in TEXT, whereas OFS
was administered by random assignment in SOFT, possibly
prompted the prescription of chemotherapy for some SOFT
patients. For instance, more patients younger than 40 years
of age (47.8% and 28.4%) and with node-negative disease
(41.5% and 31.4%) received chemotherapy in SOFT than
in TEXT. This also can be inferred by the higher median
composite risk in TEXT patients in the no-chemotherapy
cohorts (eg, 21.5% of patients who received endocrine
therapy alone in TEXT had one to three positive nodes;
Fig 4) compared with 8.6% in SOFT. These different clinical
characteristics of women who received adjuvant chemo-
therapy in SOFT and TEXT might partly explain the slightly
different absolute improvements. Premenopausal women
represented approximately 30% of patients in the clinical
trials that addressed the added benefit of adjuvant che-
motherapy over endocrine therapy18-20 in HR-positive/
HER2-negative breast cancer. Tamoxifen was the standard
of care in premenopausal women when these trials were
designed and conducted, and the additional benefit of
adjuvant chemotherapy in this age-group cannot be ex-
trapolated to women treated with combined endocrine
therapy as in TEXT and SOFT. The Rx for Positive Node,
Endocrine Responsive Breast Cancer (RxPONDER) trial
(ClinicalTrials.gov identifier: NCT01272037) enrolled pa-
tients with one to three positive nodes between 2011 and
2015 who may have received combined endocrine therapy
and could provide additional insight for intermediate-risk
patients.
Several gene expression assays also have been developed
for postmenopausal women21 to estimate better the risk of
early (0 to 5 years) and late (5 to 10 years) distant
recurrence22-24 of patients with HR-positive early breast
cancer and tailor their adjuvant endocrine treatment. None
of these tests was developed to select which endocrine
therapy is more appropriate according to genomic risk. The
prognostic information provided by these assays should not
be interpreted automatically as a prediction of treatment
benefit.25 Although the risk of late distant recurrence is
seemingly similar across age-groups,13 the different algo-
rithms cannot be applied to premenopausal patients
without further validation because most of the data derive
from postmenopausal women.
The 5% to 15% absolute improvement in freedom from
distant recurrence from escalating endocrine therapy to
tamoxifen plus OFS or exemestane plus OFS needs to be
integrated in the clinical situation of each individual patient.
The results in patients at higher risk of recurrence who
received chemotherapy are of particular clinical relevance.
A retrospective cohort study of 1,616 women showed that
the median time to all-cause mortality was significantly
longer in women with locoregional recurrence than in those
with distant metastases (6.4 v 3.4 years, respectively).26
Moreover, the 10-year survival rate of 101 women with local
recurrence was 56% compared with 9% in those with
distant recurrence.27 In patients with HER2-negative disease
who did not receive adjuvant chemotherapy, themajority with
a lower risk of recurrence, after 8 to 9 years median follow-up
in SOFT and TEXT, very few distant recurrences (23 and 35,
respectively) occurred. In these patients, the benefit of
treatment escalation is derived largely from locoregional and
contralateral breast cancer reduction.7 Given the impact on
patients’ quality of life from escalating endocrine therapy,28
clinicians need to weigh the risk of recurrence and the ex-
pected absolute improvement in disease outcomes carefully
against the added adverse effects.
With all women beyond the 5-year treatment period, the
toxicity profiles of exemestane plus OFS and tamoxifen plus
OFS are similar to postmenopausal women, and no new
toxicity signal has emerged.8 Nonadherence and early
discontinuation of oral adjuvant endocrine therapy is fre-
quent among young women29 and associated with reduced
overall survival.30 In TEXT/SOFT, early discontinuation of all
assigned endocrine therapy was approximately 20% in
each treatment group, which is in line with published
data.29 Several demographic and clinical characteristics
can help physicians to identify patients at risk for non-
persistence/adherence.31 By better quantifying treatment
benefits in the individual patient, our results may allow for
a more-tailored risk/benefit discussion and an increase in
women’s motivation, particularly those at highest risk of
distant recurrence, to follow treatment prescriptions.
Given the potential for late recurrences of HR-positive
breast cancer, conclusions about overall survival remain
premature. In postmenopausal women, the benefit of
aromatase inhibitors versus tamoxifen on breast cancer
mortality only emerged at 10 years14 (2.1% absolute gain,
14.2% v 12.1%, respectively).
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The current results add to our earlier study7 to assist
physicians and patients with estimating the individual risk-
based benefit of escalating endocrine therapy. A recent
survey showed that practicing US medical oncologists
underestimated the absolute improvement in 5-year free-
dom from breast cancer with the use of aromatase
inhibitors plus OFS versus tamoxifen for high-risk patients
(physician estimate, 5.9%) compared with our previous
study findings of 10% to 15%.7,32 An online tool is in de-
velopment to assist clinicians with using SOFT/TEXT in their
daily practice risk/benefit calculations in premenopausal
women with HR-positive/HER2-negative breast cancer.
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APPENDIX
Excluded
 Submitted material; not HR positive
Ineligible (locally determined HR negative)
  Tumor HER2 positive by central or local determination
(n = 816)
(n = 64)
(n = 5)
(n = 747)
TEXT and SOFT ITT
(N = 5,707)
TEXT and SOFT 
HR-positive/HER2-negative
analysis population
(n = 4,891)
SOFT no chemotherapy
EXEM + OFS
   TAM + OFS
   TAM
(n = 1,353)
(n = 454)
(n = 449)
(n = 450)
TEXT no chemotherapy
EXEM + OFS
TAM + OFS
(n = 991)
(n = 493)
(n = 498)
TEXT chemotherapy
 EXEM + OFS
TAM + OFS
(n = 1,276)
(n = 644)
(n = 632)
SOFT prior chemothearpy
 EXEM + OFS
  TAM + OFS
 TAM
(n = 1,271)
(n = 416)
(n = 423)
(n = 432)
FIG A1. Flow diagram of the 4,891 patients included in the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT)
hormone receptor (HR)–positive/human epidermal growth factor receptor 2 (HER2)–negative analysis population. EXEM, exemastane; ITT, intent to treat;
OFS, ovarian function suppression; TAM, tamoxifen.
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FIG A2. Kaplan-Meier estimates of 8-year freedom from distant recurrence in seven clinicopathologic subgroups, according to treatment assignment,
separately by trial. The plotted values are provided in Tables A2 and A5. Unknown values are omitted. ER, estrogen receptor; EXEM, exemestane; Ki-67,
Ki-67 labeling index; PgR, progesterone receptor; OFS, ovarian function suppression; SOFT, Suppression of Ovarian Function Trial; TAM, tamoxifen;
TEXT, Tamoxifen and Exemestane Trial.
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DRFI
TEXT HR positive/HER2 negative 81 1,137 113 1,130 0.69   0.52 to 0.92
Age at randomization, years
< 35 20 94 20 84 0.87   0.47 to 1.61
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40-44 23 392 35 391
45-49 16 373 24 415
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No. of nodes positive
160 592 31 585
1-3 27 379 39 395
≥ 4 38 166 43 150
Tumor size, cm
≤ 2 25 686 38 698
> 2 55 438 74 421
Unknown 1 13 1 11
ER expression, %
< 50 6 46 8 39
≥ 50 74 1,072 104 1,070
Unknown 1 19 1 21
PgR expression, %
< 20 18 114 25 107
20-49 10 106 20 97
≥ 50 51 894 67 904
Unknown 2 23 1 22
Tumor grade
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FIG A3. Estimated relative treatment effects on distance recurrence–free interval (DRFI) overall and according to seven clinicopathologic subgroups
for the hormone receptor (HR)–positive/human epidermal growth factor receptor (HER2)–negative analysis population. The hazard ratios were
estimated from Cox proportional hazards models stratified by cohort. Estimates not provided for unknown groups of , 50 patients. Estimates in
subgroups having few events should be interpreted with caution. (A) The Tamoxifen and Exemestane Trial (TEXT) cohorts comparing exemestane
(EXE)1 ovarian function suppression (OFS) versus tamoxifen (TAM)1 OFS. (B) Combined TEXT and Suppression of Ovarian Function Trial (SOFT)
cohorts comparing EXE1 OFS versus TAM1 OFS. (C) SOFT cohorts comparing EXE1 OFS versus TAM. (D) SOFT cohorts comparing TAM1 OFS
versus TAM. ER, estrogen receptor; Ki-67, Ki67 labeling index; PgR, progesterone receptor.
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DRFI Subgroups for Combined SOFT + TEXT HR Positive/HER2 Negative
0.25 0.5 0.69 1 2 4
Favors EXEM + OFS Favors TAM + OFS
DRFI
HR positive/HER2 negative 142 2,007 202 2,002 0.69  0.55 to 0.85
Age at randomization, years
< 35 31 183 37 166
35-39 43 333 56 312
40-44 38 633 58 659
45-49 25 654 43 692
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No. of nodes positive
320 1,192 56 1,165
1-3 44 575 73 606
≥ 4 66 240 73 231
Tumor size, cm
≤ 2 47 1,297 60 1,277
> 2 91 682 134 691
Unknown 4 28 8 34
ER expression, %
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≥ 50 127 1,889 186 1,896
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PgR expression, %
< 20 32 222 42 190
20-49 18 171 33 165
≥ 50 88 1,575 123 1,610
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FIG A3. (Continued).
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Subgroup Hazard Ratio 95% CI
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FIG A3. (Continued).
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Subgroup Hazard Ratio 95% CI
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≤ 2 22 579 38 602
> 2 60 270 45 259
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< 50 4 32 11 37
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PgR expression, %
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20-49 13 68 12 64
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FIG A3. (Continued).
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FIG A4. Subpopulation treatment effect pattern plots (STEPP) of 8-year freedom from distant recurrence (y-axis) according to median composite risk in
subpopulations (x-axis) and histograms of the composite risk distributions for each of (continued on following page)the four cohorts in the hormone receptor
(HR)–positive/human epidermal growth factor receptor 2 (HER2)–negative analysis population according to treatment assignment. The horizontal lines above
each histogram indicate the ranges of composite risks in subpopulations that are plotted at the subpopulation median composite risk value in each
corresponding STEPP. The red vertical line on the histograms indicates the selected composite risk, and intersects one or more subpopulations in which the
composite risk value is represented. The dark orange circles on the STEPPs indicate the corresponding subpopulations in which the selected composite risk is
represented. The black vertical dashed lines indicate the median composite risk of 1.42 in the overall HR-positive/HER2-negative analysis population. Three
scenarios are presented: (A) A high-risk scenario (composite risk5 3.00; 35-39 years of age, pT2pN1a, grade 3, estrogen receptor [ER] $ 50%, progesterone
receptor [PgR] $ 50% and Ki-67 labeling index [Ki-67] $ 26%). In this scenario, there are no circles on the Tamoxifen and Exemestane Trial (TEXT) no
chemotherapy and Suppression of Ovarian Function Trial (SOFT) no chemotherapy STEPPs because there were too few patients with the same or similar
composite risk values.
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FIG A4. (Continued). (B) An intermediate-risk scenario (composite risk5 1.78; 40-44 years of age, pT1pN1a, grade 2, ER$ 50%, PgR
$ 50%, and Ki-67 20-25%).
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FIG A4. (Continued). (C) A low-risk scenario (composite risk5 0.89; 40-44 years of age, pT1pN0, grade 2, ER$ 50%, PgR$ 50%, and Ki-67 14-19%).
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TABLE A1. Clinicopathologic Characteristics of the HR-Positive/HER2-Negative Analysis Population of TEXT and SOFT Overall and According to
Cohort Defined by Trial and Chemotherapy Use
TEXT
Chemotherapy
SOFT Prior
Chemotherapy
TEXT No
Chemotherapy
SOFT No
Chemotherapy All Patients
Characteristic No. % No. % No. % No. % No. %
No. of patients 1,276 100 1,271 100 991 100 1,353 100 4,891 100
Age at random assignment, years
, 35 141 11.1 232 18.3 37 3.7 20 1.5 430 8.8
35-39 221 17.3 375 29.5 113 11.4 103 7.6 812 16.6
40-44 442 34.6 407 32.0 341 34.4 370 27.3 1,560 31.9
45-49 403 31.6 213 16.8 385 38.8 625 46.2 1,626 33.2
$ 50 69 5.4 44 3.5 115 11.6 235 17.4 463 9.5
No. of positive nodes
0 401 31.4 527 41.5 776 78.3 1,235 91.3 2,939 60.1
1-3 561 44.0 510 40.1 213 21.5 117 8.6 1,401 28.6
$ 4 314 24.6 234 18.4 2 0.2 1 0.1 551 11.3
Tumor size, cm
Unknown 21 1.6 50 3.9 3 0.3 9 0.7 83 1.7
# 2 593 46.5 630 49.6 791 79.8 1,162 85.9 3,176 64.9
. 2 662 51.9 591 46.5 197 19.9 182 13.5 1,632 33.4
ER expression, %
Unknown 23 1.8 17 1.3 17 1.7 14 1.0 71 1.5
, 50 65 5.1 75 5.9 20 2.0 36 2.7 196 4.0
$ 50 1,188 93.1 1,179 92.8 954 96.3 1,303 96.3 4,624 94.5
PgR expression, %
Unknown 26 2.0 23 1.8 19 1.9 22 1.6 90 1.8
, 20 163 12.8 233 18.3 58 5.9 55 4.1 509 10.4
20-49 133 10.4 131 10.3 70 7.1 66 4.9 400 8.2
$ 50 954 74.8 884 69.6 844 85.2 1,210 89.4 3,892 79.6
Tumor grade
1 165 12.9 199 15.7 252 25.4 504 37.3 1,120 22.9
2 725 56.8 729 57.4 587 59.2 724 53.5 2,765 56.5
3 386 30.3 343 27.0 152 15.3 125 9.2 1,006 20.6
Ki-67 expression, %
Unknown 240 18.8 266 20.9 189 19.1 270 20.0 965 19.7
, 14 199 15.6 248 19.5 269 27.1 506 37.4 1,222 25.0
14-19 293 23.0 303 23.8 262 26.4 324 23.9 1,182 24.2
20-25 234 18.3 216 17.0 135 13.6 152 11.2 737 15.1
$ 26 310 24.3 238 18.7 136 13.7 101 7.5 785 16.0
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; Ki-67, Ki-67 labeling index;
PgR, progesterone receptor; SOFT, Suppression of Ovarian Function Trial; TEXT, Tamoxifen and Exemestane Trial.
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TABLE A2. TEXT: Kaplan-Meier Estimates of 8-Year Freedom From DR in Clinicopathologic Subgroups According to Treatment Assignment
Characteristic Patients DRs
Exemestane Plus OFS,
8-Year % (95% CI)
Tamoxifen Plus OFS,
8-Year % (95% CI)
All patients 2,267 194 93.2 (91.5 to 94.6) 90.1 (88.0 to 91.8)
Age at random assignment, years
, 35 178 40 77.5 (66.6 to 85.3) 75.5 (63.8 to 83.8)
35-39 334 48 91.7 (86.1 to 95.1) 82.8 (75.5 to 88.1)
40-44 783 58 93.5 (90.3 to 95.7) 90.8 (87.2 to 93.4)
45-49 788 40 96.1 (93.4 to 97.7) 93.8 (90.7 to 95.9)
$ 50 184 8 98.0 (92.2 to 99.5) 96.1 (88.2 to 98.7)
No. of positive nodes
0 1,177 47 98.0 (96.3 to 98.9) 94.9 (92.5 to 96.5)
1-3 774 66 93.7 (90.6 to 95.8) 90.6 (87.0 to 93.2)
$ 4 316 81 75.7 (67.8 to 81.9) 70.2 (61.5 to 77.3)
Tumor size, cm
# 2 1,384 63 96.9 (95.1 to 98.1) 94.9 (92.8 to 96.4)
. 2 859 129 87.6 (83.9 to 90.5) 82.0 (77.7 to 85.5)
Unknown 24 2
ER expression, %
, 50 85 14 87.5 (72.4 to 94.7) 80.3 (63.0 to 90.1)
$ 50 2,142 178 93.5 (91.7 to 94.9) 90.3 (88.2 to 92.1)
Unknown 40 2
PgR expression, %
, 20 221 43 82.1 (72.9 to 88.4) 75.5 (65.6 to 82.9)
20-49 203 30 90.7 (82.8 to 95.0) 80.9 (70.9 to 87.7)
$ 50 1,798 118 95.1 (93.3 to 96.4) 92.8 (90.7 to 94.4)
Unknown 45 3
Tumor grade
1 417 8 97.8 (94.1 to 99.2) 99.0 (95.9 to 99.7)
2 1,312 98 94.9 (92.7 to 96.5) 91.2 (88.6 to 93.3)
3 538 88 85.7 (80.6 to 89.6) 79.7 (73.7 to 84.4)
Ki-67 expression, %
, 14 468 10 97.1 (93.0 to 98.8) 98.6 (95.6 to 99.5)
14-19 555 30 95.9 (92.4 to 97.8) 94.2 (90.3 to 96.5)
20-25 369 48 91.3 (85.6 to 94.8) 83.2 (76.3 to 88.2)
$ 26 446 71 88.3 (83.1 to 92.0) 78.7 (72.0 to 84.0)
Unknown 429 35 93.1 (88.5 to 95.9) 91.7 (86.6 to 94.9)
NOTE. Estimates not provided for unknown groups of , 50 patients. Estimates in subgroups that had few events should be interpreted with
caution.
Abbreviations: DR, distant recurrence; ER, estrogen receptor; Ki-67, Ki-67 labeling index; OFS, ovarian function suppression; PgR,
progesterone receptor; TEXT, Tamoxifen and Exemestane Trial.
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TABLE A3. TEXT: Kaplan-Meier Estimates of 8-Year Freedom From DR in Clinicopathologic Subgroups According to Chemotherapy Use and
Treatment Assignment
Chemotherapy
No Chemotherapy
Characteristic Patients DRs
Exemestane Plus OFS,
8-Year % (95% CI)
Tamoxifen Plus OFS,
8-Year % (95% CI) Patients DRs 8-Year % (95% CI)
All patients 1,276 159 90.0 (87.2 to 92.2) 84.9 (81.6 to 87.6) 991 35 97.0 (95.5 to 97.9)
Age at random assignment, years
, 35 141 36 73.9 (61.2 to 83.0) 73.2 (59.4 to 82.9) 37 4 87.5 (69.7 to 95.2)
35-39 221 37 89.0 (81.3 to 93.6) 78.7 (68.6 to 85.9) 113 11 93.3 (86.5 to 96.8)
40-44 442 49 90.3 (84.9 to 93.8) 85.6 (79.9 to 89.8) 341 9 97.8 (95.3 to 98.9)
45-49 403 31 95.0 (90.6 to 97.4) 89.7 (84.3 to 93.4) 385 9 97.6 (95.0 to 98.9)
$ 50 69 6 97.6 (83.9 to 99.7) 88.7 (69.0 to 96.2) 115 2 99.1 (93.7 to 99.9)
No. of positive nodes
0 401 20 98.4 (95.0 to 99.5) 92.9 (87.8 to 95.9) 776 27 96.8 (95.1 to 97.9)
1-3 561 58 92.8 (88.8 to 95.4) 87.2 (82.4 to 90.7) 213 8 97.5 (93.9 to 98.9)
$ 4 314 81 75.7 (67.8 to 81.9) 70.2 (61.5 to 77.3) 2 0
Tumor size, cm
# 2 593 38 95.6 (92.2 to 97.6) 92.6 (88.5 to 95.2) 791 25 97.2 (95.6 to 98.3)
. 2 662 119 85.3 (80.8 to 88.8) 77.7 (72.5 to 82.1) 197 10 95.7 (91.6 to 97.8)
Unknown 21 2 3 0 —
ER expression, %
, 50 65 13 83.7 (65.1 to 92.9) 74.5 (53.8 to 87.0) 20 1
$ 50 1,188 144 90.4 (87.6 to 92.7) 85.3 (82.0 to 88.1) 954 34 96.8 (95.3 to 97.8)
Unknown 23 2 17 1 —
PgR expression, %
, 20 163 36 79.6 (68.7 to 87.0) 72.5 (60.2 to 81.6) 58 7 85.8 (72.1 to 93.1)
20-49 133 25 87.6 (76.6 to 93.6) 75.0 (61.2 to 84.5) 70 5 94.1 (85.0 to 97.7)
$ 50 954 95 92.6 (89.7 to 94.8) 88.0 (84.5 to 90.8) 844 23 97.9 (96.5 to 98.7)
Unknown 26 3 19 0 —
Tumor grade
1 165 6 93.6 (83.8 to 97.6) 98.7 (91.2 to 99.8) 252 2 99.6 (97.0 to 99.9)
2 725 81 92.7 (89.2 to 95.0) 85.4 (80.9 to 88.9) 587 17 97.9 (96.1 to 98.9)
3 386 72 83.7 (77.3 to 88.4) 77.2 (69.8 to 83.0) 152 16 88.4 (81.3 to 92.9)
Ki-67 expression, %
, 14 199 8 94.6 (86.2 to 98.0) 97.9 (92.0 to 99.5) 269 2 98.9 (95.7 to 99.7)
14-19 293 26 92.3 (86.1 to 95.8) 89.9 (83.3 to 94.1) 262 4 99.6 (97.2 to 99.9)
20-25 234 41 90.1 (82.2 to 94.6) 76.5 (67.1 to 83.6) 135 7 94.5 (88.1 to 97.6)
$ 26 310 58 86.0 (79.4 to 90.5) 74.9 (66.1 to 81.6) 136 13 90.0 (82.8 to 94.2)
Unknown 240 26 90.0 (82.6 to 94.3) 86.9 (78.5 to 92.2) 189 9 97.1 (93.3 to 98.8)
NOTE. Estimates provided for treatment groups combined in the no-chemotherapy cohort because of a small number of events and were not
reported when # 20 patients. Estimates not provided for unknown groups of , 50 patients overall. Estimates in subgroups that had few events
should be interpreted with caution.
Abbreviations: DR, distant recurrence; ER, estrogen receptor; Ki-67, Ki-67 labeling index; OFS, ovarian function suppression; PgR,
progesterone receptor; TEXT, Tamoxifen and Exemestane Trial.
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TABLE A4. Combined SOFT and TEXT Cohorts Treated With Ovarian Suppression: Kaplan-Meier Estimates of 8-Year Freedom From DR in
Clinicopathologic Subgroups According to Treatment Assignment
Characteristic Patients DRs
Exemestane Plus OFS,
8-Year % (95% CI)
Tamoxifen Plus OFS,
8-Year % (95% CI)
All patients 4,009 344 93.1 (91.8 to 94.2) 89.8 (88.3 to 91.1)
Age at random assignment, years
, 35 349 68 82.3 (75.5 to 87.4) 76.2 (68.4 to 82.4)
35-39 645 99 87.7 (83.3 to 91.0) 82.7 (77.6 to 86.7)
40-44 1,292 96 93.6 (91.2 to 95.4) 90.8 (88.2 to 92.9)
45-49 1,346 68 96.6 (94.7 to 97.8) 93.8 (91.5 to 95.5)
$ 50 377 13 98.5 (95.3 to 99.5) 95.3 (90.2 to 97.7)
No. of positive nodes
0 2,357 88 97.9 (96.8 to 98.7) 95.2 (93.7 to 96.4)
1-3 1,181 117 92.6 (90.0 to 94.6) 88.0 (84.9 to 90.4)
$ 4 471 139 70.9 (64.2 to 76.6) 67.7 (60.8 to 73.7)
Tumor size, cm
# 2 2,574 107 96.7 (95.4 to 97.6) 95.3 (93.9 to 96.4)
. 2 1,373 225 86.7 (83.7 to 89.1) 80.4 (77.0 to 83.3)
Unknown 62 12 88.4 (68.2 to 96.1) 75.3 (56.6 to 86.8)
ER expression, %
, 50 159 25 87.3 (77.5 to 93.0) 83.3 (71.9 to 90.4)
$ 50 3,785 313 93.4 (92.1 to 94.5) 90.1 (88.6 to 91.4)
Unknown 65 6 91.1 (68.8 to 97.7) 86.7 (68.2 to 94.8)
PgR expression, %
, 20 412 74 83.7 (77.6 to 88.2) 76.2 (69.0 to 82.0)
20-49 336 51 91.0 (85.3 to 94.6) 80.3 (72.9 to 85.8)
$ 50 3,185 211 94.8 (93.5 to 95.9) 92.5 (91.0 to 93.7)
Unknown 76 8 86.8 (68.4 to 94.8) 87.3 (69.4 to 95.0)
Tumor grade
1 880 16 98.4 (96.3 to 99.3) 98.2 (96.3 to 99.2)
2 2,291 191 93.7 (92.0 to 95.1) 90.0 (88.0 to 91.7)
3 838 137 86.0 (82.0 to 89.1) 80.5 (76.0 to 84.2)
Ki-67 expression, %
, 14 986 33 96.6 (94.2 to 98.0) 97.0 (94.8 to 98.2)
14-19 970 59 95.0 (92.5 to 96.7) 93.2 (90.4 to 95.3)
20-25 607 77 90.6 (86.4 to 93.6) 83.9 (78.9 to 87.9)
$ 26 670 114 87.1 (82.9 to 90.4) 78.2 (73.0 to 82.5)
Unknown 776 61 93.6 (90.4 to 95.8) 90.9 (87.3 to 93.5)
NOTE. Estimates not provided for unknown groups of , 50 patients. Estimates in subgroups that had few events should be interpreted with
caution.
Abbreviations: DR, distant recurrence; ER, estrogen receptor; Ki-67, Ki-67 labeling index; OFS, ovarian function suppression; PgR,
progesterone receptor; SOFT, Suppression of Ovarian Function Trial; TEXT, Tamoxifen and Exemestane Trial.
Journal of Clinical Oncology
Freedom From Distant Recurrence With Endocrine Therapies
Downloaded from ascopubs.org by Instituto Europeo Di Oncologia on April 16, 2020 from 193.204.098.002
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
TABLE A5. SOFT: Kaplan-Meier Estimates of 8-Year Freedom From DR in Clinicopathologic Subgroups According to Treatment Assignment
Characteristic Patients DRs
Exemestane Plus OFS,
8-Year % (95% CI)
Tamoxifen Plus OFS,
8-Year % (95% CI)
Tamoxifen,
8-Year % (95% CI)
All patients 2,624 239 93.0 (90.9 to 94.6) 89.5 (87.2 to 91.5) 89.7 (87.3 to 91.7)
Age at random assignment, years
, 35 252 48 87.2 (78.0 to 92.7) 77.4 (66.0 to 85.3) 74.5 (62.5 to 83.1)
35-39 478 81 83.1 (75.5 to 88.6) 82.6 (74.7 to 88.2) 79.7 (71.4 to 85.8)
40-44 777 62 93.9 (89.7 to 96.4) 91.0 (86.7 to 93.9) 91.8 (87.4 to 94.6)
45-49 838 38 97.2 (94.2 to 98.7) 93.8 (90.0 to 96.2) 95.9 (92.3 to 97.8)
$ 50 279 10 99.0 (92.9 to 99.9) 94.6 (86.1 to 98.0) 95.2 (87.7 to 98.2)
No. of positive nodes
0 1,762 67 97.9 (96.1 to 98.8) 95.6 (93.4 to 97.1) 95.3 (92.8 to 96.9)
1-3 627 85 90.6 (85.3 to 94.1) 83.0 (76.8 to 87.7) 85.5 (79.7 to 89.7)
$ 4 235 87 60.3 (47.3 to 71.0) 63.5 (51.5 to 73.2) 59.0 (46.0 to 69.8)
Tumor size, cm
# 2 1,792 82 96.4 (94.5 to 97.7) 95.9 (93.6 to 97.3) 93.6 (91.0 to 95.5)
. 2 773 141 84.9 (79.3 to 89.1) 77.9 (72.2 to 82.6) 81.7 (75.9 to 86.2)
Unknown 59 16 85.1 (52.3 to 96.1) 69.6 (46.6 to 84.2) 73.9 (48.2 to 88.2)
ER expression, %
, 50 111 22 87.0 (71.2 to 94.4) 86.7 (68.3 to 94.8) 70.1 (51.0 to 82.8)
$ 50 2,482 212 93.3 (91.2 to 94.9) 89.9 (87.5 to 91.9) 90.6 (88.2 to 92.5)
Unknown 31 5
PgR expression, %
, 20 288 53 85.6 (76.9 to 91.3) 77.2 (65.4 to 85.5) 76.5 (66.2 to 84.1)
20-49 197 33 91.6 (81.0 to 96.5) 79.7 (67.6 to 87.7) 81.4 (68.8 to 89.3)
$ 50 2,094 146 94.4 (92.2 to 96.0) 92.2 (89.8 to 94.1) 92.3 (89.7 to 94.2)
Unknown 45 7
Tumor grade
1 703 19 98.9 (95.7 to 99.7) 97.6 (94.2 to 99.0) 95.9 (91.7 to 98.0)
2 1,453 142 92.1 (89.1 to 94.3) 88.4 (85.0 to 91.1) 90.0 (86.6 to 92.5)
3 468 78 86.6 (79.6 to 91.4) 81.9 (74.7 to 87.2) 79.9 (72.1 to 85.7)
Ki-67 expression, %
, 14 754 39 96.2 (92.4 to 98.1) 95.4 (91.5 to 97.5) 93.0 (88.0 to 96.0)
14-19 627 45 94.0 (89.7 to 96.6) 92.2 (87.3 to 95.2) 93.0 (88.0 to 95.9)
20-25 368 43 89.5 (81.8 to 94.0) 84.8 (76.3 to 90.4) 87.6 (79.8 to 92.6)
$ 26 339 66 84.7 (76.2 to 90.4) 77.2 (68.1 to 84.0) 79.2 (70.0 to 85.8)
Unknown 536 81 94.4 (89.0 to 97.2) 90.0 (84.1 to 93.7) 89.8 (84.3 to 93.5)
NOTE. Estimates not provided for unknown groups of , 50 patients. Estimates in subgroups that had few events should be interpreted with
caution.
Abbreviations: DR, distant recurrence; ER, estrogen receptor; Ki-67, Ki-67 labeling index; OFS, ovarian function suppression; PgR,
progesterone receptor; SOFT, Suppression of Ovarian Function Trial.
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TABLE A6. SOFT: Kaplan-Meier Estimates of 8-Year Freedom From DR in Clinicopathologic Subgroups According to Chemotherapy Use and Treatment
Assignment
Prior Chemotherapy
No Chemotherapy
Characteristic Patients DRs
Exemestane Plus OFS,
8-Year % (95% CI)
Tamoxifen Plus OFS,
8-Year % (95% CI)
Tamoxifen,
8-Year % (95% CI) Patients DRs 8-Year % (95% CI)
All patients 1,271 216 86.2 (82.2 to 89.4) 80.3 (75.9 to 84.0) 81.0 (76.6 to 84.6) 1,353 23 98.5 (97.6 to 99.1)
Age at randomassignment, years
, 35 232 48 86.0 (76.2 to 92.0) 75.3 (63.2 to 83.9) 72.9 (60.4 to 82.0) 20 0
35-39 375 79 79.7 (70.8 to 86.2) 77.4 (67.7 to 84.5) 75.9 (66.2 to 83.2) 103 2 96.6 (85.5 to 99.2)
40-44 407 53 90.0 (82.6 to 94.4) 83.5 (76.1 to 88.9) 88.1 (81.2 to 92.5) 370 9 97.8 (95.3 to 99.0)
45-49 213 29 90.1 (79.2 to 95.5) 82.0 (70.9 to 89.2) 84.1 (70.8 to 91.7) 625 9 99.2 (98.0 to 99.7)
$ 50 44 7 93.3 (61.3 to 99.0) 87.5 (38.7 to 98.1) 77.0 (49.7 to 90.7) 235 3 98.5 (95.4 to 99.5)
No. of positive nodes
0 527 47 94.2 (89.0 to 97.0) 89.1 (82.8 to 93.1) 88.2 (81.3 to 92.6) 1,235 20 98.7 (97.8 to 99.2)
1-3 510 82 89.2 (83.0 to 93.3) 79.7 (72.3 to 85.3) 83.4 (76.8 to 88.2) 117 3 96.0 (87.0 to 98.8)
$ 4 234 87 60.3 (47.3 to 71.0) 63.5 (51.5 to 73.2) 58.3 (45.2 to 69.3) 1 0
Tumor size, cm
# 2 630 70 90.5 (85.5 to 93.9) 90.4 (84.8 to 94.0) 84.1 (77.7 to 88.8) 1,162 12 99.1 (98.2 to 99.5)
. 2 591 130 81.6 (74.7 to 86.8) 71.6 (64.4 to 77.6) 79.0 (72.3 to 84.2) 182 11 94.7 (89.3 to 97.4)
Unknown 50 16 83.3 (48.2 to 95.6) 66.7 (42.5 to 82.5) 64.6 (34.7 to 83.5) 9 0 —
ER expression, %
, 50 75 20 80.9 (59.4 to 91.7) 81.0 (56.7 to 92.4) 61.3 (36.4 to 78.9) 36 2 94.4 (79.6 to 98.6)
$ 50 1,179 191 86.7 (82.6 to 89.9) 80.7 (76.1 to 84.5) 82.1 (77.6 to 85.8) 1,303 21 98.6 (97.7 to 99.2)
Unknown 17 5 14 0 —
PgR expression, %
, 20 233 52 82.9 (72.7 to 89.5) 70.5 (56.1 to 81.0) 72.1 (60.0 to 81.1) 55 1 98.1 (87.6 to 99.7)
20-49 131 32 90.6 (76.8 to 96.4) 64.4 (46.5 to 77.6) 73.5 (57.2 to 84.5) 66 1 98.4 (89.4 to 99.8)
$ 50 884 125 87.0 (82.1 to 90.7) 84.9 (80.1 to 88.6) 84.4 (79.2 to 88.4) 1,210 21 98.5 (97.5 to 99.1)
Unknown 23 7 22 0 —
Tumor grade
1 199 15 96.4 (85.9 to 99.1) 92.3 (80.8 to 97.1) 90.3 (79.5 to 95.5) 504 4 99.2 (97.4 to 99.8)
2 729 127 85.1 (79.5 to 89.2) 78.9 (72.8 to 83.8) 82.4 (76.4 to 86.9) 724 15 98.3 (96.8 to 99.0)
3 343 74 82.5 (73.3 to 88.8) 77.4 (68.3 to 84.1) 72.8 (63.0 to 80.5) 125 4 97.5 (92.5 to 99.2)
Ki-67 expression, %
, 14 248 33 88.5 (77.8 to 94.3) 86.5 (75.6 to 92.8) 81.8 (69.7 to 89.4) 506 6 99.4 (97.5 to 99.9)
14-19 303 40 87.6 (79.2 to 92.8) 85.3 (76.4 to 91.0) 88.7 (79.9 to 93.8) 324 5 98.5 (95.8 to 99.5)
20-25 216 38 85.8 (74.4 to 92.3) 76.4 (63.8 to 85.0) 80.6 (67.8 to 88.7) 152 5 96.5 (91.8 to 98.5)
$ 26 238 61 78.6 (66.9 to 86.6) 72.1 (60.7 to 80.7) 71.4 (59.6 to 80.2) 101 5 96.0 (89.6 to 98.5)
Unknown 266 44 88.8 (78.6 to 94.3) 80.3 (69.4 to 87.6) 81.0 (71.1 to 87.7) 270 2 99.1 (96.4 to 99.8)
NOTE. Estimates provided for treatment groups combined in the no-chemotherapy cohort because of the small number of events and not provided when
# 20 patients. Estimates not provided for unknown groups of, 50 patients overall (chemotherapy and no-chemotherapy combined). Estimates in subgroups
that had a few events should be interpreted with caution.
Abbreviations: DR, distant recurrence; ER, estrogen receptor; Ki-67, Ki-67 labeling index; OFS, ovarian function suppression; PgR, progesterone receptor;
SOFT, Suppression of Ovarian Function Trial.
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TABLE A7. Distribution of the Composite Measures of Recurrence Risk in Clinicopathologic Subgroups
Composite Risk
Measure Patients DRs Median Quartile 1 Quartile 3 Minimum Maximum
All HR-positive/HER2-negative 4,891 433 1.42 0.81 2.16 –0.28 4.60
Age at random assignment, years
, 35 430 88 2.49 1.95 3.16 0.67 4.59
35-39 812 129 2.01 1.49 2.80 0.52 4.60
40-44 1,560 120 1.44 0.89 2.02 0.07 3.84
45-49 1,626 78 1.07 0.72 1.65 20.28 4.01
$ 50 463 18 0.79 0.50 1.36 20.04 3.87
No. of positive nodes
0 2,939 114 0.98 0.72 1.47 20.28 3.26
1-3 1,401 151 1.91 1.42 2.43 0.44 3.91
$ 4 551 168 3.18 2.71 3.59 1.30 4.60
Tumor size, cm
Unknown 83 18 2.49 2.13 3.15 0.89 4.60
# 2 3,176 145 1.07 0.72 1.59 20.28 4.01
. 2 1,632 270 2.27 1.73 2.92 0.48 4.59
ER expression, %
Unknown 71 7 1.85 1.61 2.42 20.28 4.60
, 50 196 36 2.10 1.32 2.96 0.06 4.59
$ 50 4,624 390 1.39 0.77 2.09 20.10 4.44
PgR expression, %
Unknown 90 10 2.14 1.67 2.63 0.90 4.60
, 20 509 96 2.37 1.79 3.03 0.36 4.59
20-49 400 63 2.14 1.40 2.90 0.21 4.32
$ 50 3,892 264 1.29 0.73 1.89 20.28 4.03
Tumor grade
1 1,120 27 0.35 0.06 0.75 20.28 2.94
2 2,765 240 1.46 0.98 2.10 0.72 4.60
3 1,006 166 2.29 1.75 2.98 0.69 4.59
Ki-67 expression, %
Unknown 965 81 1.41 0.79 2.11 20.28 4.60
, 14 1,222 49 0.75 0.17 1.39 0.00 3.82
14-19 1,182 75 1.29 0.77 1.87 20.10 3.85
20-25 737 91 1.79 1.24 2.42 0.26 4.39
$ 26 785 137 2.36 1.87 3.00 0.49 4.59
NOTE. Values of grade, ER, and PgR expression were centrally determined if available and locally determined otherwise; Ki-67 expression was
available only by central determination.
Abbreviations: DR, distant recurrence; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor;
Ki-67, Ki-67 labeling index; PgR, progesterone receptor.
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